- Home
- EVG vs FENC Comparison
EVG vs FENC Comparison
Compare EVG & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVG
- FENC
- Stock Information
- Founded
- EVG 2005
- FENC 1996
- Country
- EVG United States
- FENC United States
- Employees
- EVG N/A
- FENC N/A
- Industry
- EVG Investment Managers
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVG Finance
- FENC Health Care
- Exchange
- EVG Nasdaq
- FENC Nasdaq
- Market Cap
- EVG 149.9M
- FENC 156.9M
- IPO Year
- EVG N/A
- FENC 2001
- Fundamental
- Price
- EVG $10.98
- FENC $6.50
- Analyst Decision
- EVG
- FENC Strong Buy
- Analyst Count
- EVG 0
- FENC 2
- Target Price
- EVG N/A
- FENC $14.00
- AVG Volume (30 Days)
- EVG 49.4K
- FENC 118.9K
- Earning Date
- EVG 01-01-0001
- FENC 03-10-2025
- Dividend Yield
- EVG 8.68%
- FENC N/A
- EPS Growth
- EVG N/A
- FENC N/A
- EPS
- EVG N/A
- FENC N/A
- Revenue
- EVG N/A
- FENC $47,538,000.00
- Revenue This Year
- EVG N/A
- FENC $28.99
- Revenue Next Year
- EVG N/A
- FENC $63.21
- P/E Ratio
- EVG N/A
- FENC N/A
- Revenue Growth
- EVG N/A
- FENC 123.69
- 52 Week Low
- EVG $9.13
- FENC $3.96
- 52 Week High
- EVG $10.86
- FENC $11.29
- Technical
- Relative Strength Index (RSI)
- EVG 46.70
- FENC 48.98
- Support Level
- EVG $10.91
- FENC $6.25
- Resistance Level
- EVG $11.24
- FENC $6.90
- Average True Range (ATR)
- EVG 0.12
- FENC 0.33
- MACD
- EVG 0.01
- FENC -0.01
- Stochastic Oscillator
- EVG 43.48
- FENC 60.46
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.